Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Exercise Therapy for Women With ANOCA (ANOCA Exercise)

24. juli 2026 opdateret af: NHS Greater Glasgow and Clyde

Exercise Therapy for Women With ANOCA: a Randomised, Controlled Trial

Angina is a feeling of chest pain or discomfort which can happen if there is reduced blood flow to the heart. Patients can experience angina with no obstructive coronary arteries (ANOCA) which is a difficult condition to treat (ie relieve angina) since few randomised, controlled therapy trials have been undertaken for ANOCA. Until now, angina has been mainly studied in men even though women are at least two-fold more likely than men to experience ANOCA.

In 2023, a Scientific Statement from the American Heart Association affirmed that resistance exercise training can improve or maintain muscle mass and strength and confer favourable physiological and clinical effects on cardiovascular disease and risk factors. Resistance exercise has not been assessed in ANOCA and it offers an important opportunity to study non drug alternatives to treatment for women.

This study will use a resistance based exercise programme to investigate if symptoms of ANOCA can be improved in women. It will recruit at least 76 patients (maximum 152 patients) across 13 hospitals in the UK and the Netherlands.

The study will use a randomised wait list control design. This means all participants will be offered the intervention, but the randomisation will decide when they undergo it.

It is part of a platform of trials for women with ANOCA. We are also setting up a drug study called ANOCA Therapy and a cohort study called ANOCA- Diagnosis.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

There is a gap in knowledge on evidence-based therapy for ANOCA. Stratified medicine is a population-level diagnostic approach for identifying endotypes in a heterogenous population of all-comers. An endotype is defined as a subtype of a condition, which must be characterised by a distinct functional or pathophysiological mechanism.

Use of quantitative noninvasive and invasive diagnostic methods, such as magnetic resonance imaging and coronary function tests involving acetylcholine testing, enables more accurate identification and discrimination of causal endotypes of ANOCA. This is especially relevant for women with ANOCA who have historically been under-recognised.

Quantitative diagnostic methods should bring an end to empirical therapy, therapeutic nihilism and sex disparities in ANOCA.

Precision medicine is different. Precision medicine targets the individual (and their endotype) with a mechanism informed therapy. Accordingly, in this Wellcome Leap Visible project, we will employ a stratified medicine diagnostic approach in women with suspected ANOCA undergoing invasive CFTs in multiple hospitals and then employ a precision medicine strategy by offering each woman an endotype-informed therapy option.

Resistance exercise has not been previously investigated in ANOCA and it therefore represents a novel therapeutic option. This lifestyle intervention will increase the range of trial options, maximize patient choice for participation, and facilitate timely delivery of this project. The beneficial effects of resistance exercise on cardiovascular function have recently been endorsed in a Scientific Statement from the American Heart Association and further supported by a systematic review and favourable experience in our recent randomized trial in Long COVID.

In 2023, a Scientific Statement from the American Heart Association affirmed that resistance exercise training can improve or maintain muscle mass and strength and confer favourable physiological and clinical effects on cardiovascular disease and risk factors. In 19 men with coronary artery disease and endothelial dysfunction, indicated by abnormal acetylcholine-induced coronary vasoconstriction, a randomized controlled trial of aerobic exercise training demonstrated improvements in endothelium-dependent vasodilatation both in epicardial coronary vessels and in resistance vessels. The intervention involved an exercise program six times per day for at least 10 minutes. These results were promising but came with major limitations: no women were included in the study and the exercise program is both burdensome and impractical.

Resistance exercise has not been assessed in ANOCA. Inclusion of a non-CTIMP (lifestyle intervention) brings strategic advantages to our ANOCA platform. A non-medicinal intervention provides an accessible therapy option for women of child-bearing age and for those who may prefer not to participate in an investigational drug trial. This non-CTIMP may also become an option for women who withdraw from a CTIMP, or who complete a CTIMP and are willing to continue into a second trial. The basket trial of resistance exercise may include participants who have completed a precision medicine CTIMP who then wish to participate in the resistance exercise trial or vice versa.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

76

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

      • Basildon, Det Forenede Kongerige
        • Basildon University Hospital
      • Bath, Det Forenede Kongerige
        • Royal United Hospital Bath
      • Cambridge, Det Forenede Kongerige
        • Royal Papworth Hospital
      • Glasgow, Det Forenede Kongerige, G51 4TF
        • Queen Elizabeth University Hospital Clinical Research Facility
        • Kontakt:
      • Leeds, Det Forenede Kongerige
        • Leeds General Infirmary
      • London, Det Forenede Kongerige
        • Kings College Hospital
      • London, Det Forenede Kongerige
        • Brompton Hospital
      • London, Det Forenede Kongerige
        • Guy and St Thomas Hospital
      • Newcastle upon Tyne, Det Forenede Kongerige
        • Freeman Hospital
        • Kontakt:
          • Vijay Kunadian
      • Nottingham, Det Forenede Kongerige
        • Nottingham City Hospital
      • Sunderland, Det Forenede Kongerige
        • Sunderland Royal Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  1. Angina with no obstructive coronary arties (ANOCA)
  2. Myocardial perfusion reserve or coronary flow reserve recorded within three years
  3. Seattle Angina Questionnaire frequency score ≤60
  4. Duke Activity Status Index ≤34
  5. Female sex

Exclusion Criteria:

  1. Age <18 years
  2. Unable to provide informed consent
  3. - Unable to comply with the protocol
  4. Pregnancy
  5. Currently undertaking resistance exercise activities

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Intervention
Allocated to exercise intervention first
Participants will undergo daily resistance based exercise for 8 weeks
Aktiv komparator: Control
Allocated to exercise intervention second
Participants will undergo daily resistance based exercise for 8 weeks

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Seattle Angina Questionnaire
Tidsramme: Change from Baseline to Week 9
The Seattle Angina Questionnaire a validated 19-item patient-reported survey used to measure coronary artery disease and angina treatment efficacy. Patients will complete on paper or electronically. The scores range from 0 to 100, with higher scores indicating less frequent angina, improved function, and better quality of life.
Change from Baseline to Week 9

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Myocardial perfusion reserve (MPR)
Tidsramme: Change from baseline to week 9
The ratio of maximum blood flow in the heart muscle under stress compared to resting flow
Change from baseline to week 9
Handgrip strength using hand dynamometer
Tidsramme: Change from baseline to week 9
Measured in Kgs. This is used as a proxy for overall body strength with lower measures indicating less strength.
Change from baseline to week 9
Short Physical Performance Battery (SPPB)
Tidsramme: Change from baseline to week 9
Used as a proxy for fitness
Change from baseline to week 9
Brief Illness perception Questionnaire (Brief IPQ)
Tidsramme: Change from baseline to week 9
A nine-item scale designed to rapidly assess the cognitive and emotional representations of illness. It consists of 9 items: 8 are scored on a 0-10 scale, and item 9 is an open-ended question assessing perceived causes. The total score (0-80) is calculated by summing the first 8 items, with items 3, 4, and 7 reverse scored. Higher scores generally reflect a more threatening perception of the illness
Change from baseline to week 9
Patient Health Questionnaire-4 of (PHQ4)
Tidsramme: Change from Baseline to Week 9
An ultra-brief screening tool used to assess core symptoms of anxiety and depression. Higher scores indicate greater feelings of anxiety and depression.
Change from Baseline to Week 9
Duke Activity Status Index (DASI)
Tidsramme: From Baseline to Week 9
A 12-item, self-administered questionnaire used to estimate a patient's functional capacity and peak oxygen uptake. Scores range from 0 to 58.2, with higher scores indicating better physical fitness and lower risk
From Baseline to Week 9
EQ-5D (EQ-5D-5L)
Tidsramme: Change from Baseline to Week 9

The EQ-5D evaluates health across 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). It yields three metrics: a 5-digit health profile string, a weighted index value, and a 0-100 self-rated Visual Analogue Scale (VAS) score.

For the 5-digit health profile string higher individual numbers indicate worse health problems.

For the weighted index value a score of 1 indicates perfect health, while 0 represents death.

For the visual analogue score higher numbers here indicate better health

Change from Baseline to Week 9
International Physical Activity Questionnaire (IPAQ)
Tidsramme: Change from Baseline to Week 9
Used to obtain comparable estimates of physical activity between populations and countries. Higher scores indicate greater physical activity.
Change from Baseline to Week 9
Fatigue severity scale questionnaire
Tidsramme: Change from Baseline to Week 9
Rates level of fatigue. 9 statements assess how fatigue impacts daily life. Each statement is rated on a 7-point Likert scale, ranging from 1 (strongly disagree) to 7 (strongly agree). Higher scores indicate greater fatigue.
Change from Baseline to Week 9
Short Form Post-Exercise Malaise Questionnaire
Tidsramme: Change from Baseline to Week 9
measures symptom exacerbation by assessing frequency and severity of symptoms. Higher scores reflect a stronger indication of post exercise malaise.
Change from Baseline to Week 9
Episodes of care (primary, secondary, physiotherapy, rehabilitation)
Tidsramme: Week 9
How many times participants engaged with services
Week 9
Hospitalisation for any reason by electronic health record review (where available) up to 4 months (Visit 3)
Tidsramme: Week 17
Review of medical notes to see if the patient has been in hospital
Week 17

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Colin Berry, The University of Glasgow

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

14. september 2026

Primær færdiggørelse (Anslået)

30. juni 2029

Studieafslutning (Anslået)

30. juni 2029

Datoer for studieregistrering

Først indsendt

20. juli 2026

Først indsendt, der opfyldte QC-kriterier

24. juli 2026

Først opslået (Faktiske)

29. juli 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

29. juli 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

24. juli 2026

Sidst verificeret

1. juli 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • GN26CA170

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

A decision will be made by the TSC once the study has ended.

IPD-delingstidsramme

After the study has completed

IPD-delingsadgangskriterier

Bone fide collaboration request

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .